

November 10, 2022

To,
Listing Department
National Stock Exchange Of India Limited,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Company Code No. VIJAYA

To,
The Corporate Relations Department
BSE Limited,
Phiroz Jeejeebhoy Towers,
25<sup>th</sup> floor, Dalal Street,
Mumbai - 400 001
Company Code No. 543350

Dear Sir/Madam,

Sub: Outcome of the Board Meeting.

Ref: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We hereby inform you that the Board of Directors of the Company at their meeting held today i.e. Thursday, November 10, 2022 has, inter-alia considered and approved the following items;

- Un-audited standalone and consolidated financial results of the Company for the second quarter and half year ended September 30, 2022.
   The copy of the aforesaid un-audited financial results of the Company together with limited review report(s) of Statutory Auditor are annexed herewith.
- 2. Shifting of Registered Office of the Company from "3-6-16 & 17, Street No.19 Himayatnagar Hyderabad Telangana 500029" to "6-3-883/F,FPA Building, Near Topaz building, Punjagutta, Hyderabad Telangana 500082", which is within the local limits of the city/town.

Further the Board of Directors of the Company had taken note of the resignation submitted by Ms. Anusha Kanumuru, Company Secretary & Compliance Officer and she will be relieved from the services on or before December 31, 2022. The details as required to be disclosed in this regard, pursuant to Regulation 30 of the SEBI LODR read with SEBI Circular CIR/CFD//CMD/4/2015 are enclosed.

The meeting of the Board commenced at 12:10 p.m. and concluded at 1:35 p.m.

Kindly take the information on record.

Thanking you,
Yours faithfully,
For Vijaya Diagnostic Centre Limited

S Suprita Reddy Chief Executive Officer



## Details pertaining to cessation of Company Secretary:

Name of the KMP	Ms. Anusha Kanumuru
Reason for Cessation	Resignation
Date of cessation/Relieving	On or before December 31, 2022
Brief profile	Not Applicable

# B S R & Associates LLP

**Chartered Accountants** 

Salarpuria Knowledge City, Orwell, B Wing, 6<sup>th</sup> Floor, Unit-3, Sy No. 83/1, Plot No. 02, Raidurg, Hyderabad – 500 081 - India Telephone: +91 40 7182 2000 Fax: +91 40 7182 2399

Limited Review Report on unaudited standalone financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') for the quarter ended 30 September 2022 and year-to-date results for the period from 01 April 2022 to 30 September 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

# To the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

- We have reviewed the accompanying Statement of unaudited standalone financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Company") for the quarter ended 30 September 2022 and year-to-date results for the period from 01 April 2022 to 30 September 2022 ("the Statement").
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Associates LLP

Chartered Accountants

Firm's Registration No.:116231W/W-100024

AMIT KUMAR AMIT KUMAR BAJAJ

BAJAJ

Digitally signed by
AMIT KUMAR BAJAJ
Date: 2022.11.10
12:57:14 +05'30'

Amit Kumar Bajaj

Partner

Hyderabad 10 November 2022 Membership No.: 218685 UDIN:22218685BCRZRG8004



#### Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') CIN: L85195TG2002PLC039075

Regd. Office: 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad-500029, Telangana, India
Corporate Office: No.6-3-883/F, FPA Building, Near Rajiv Gandhi Statute Lane Adjacent to Topaz Building, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Standalone Financial Results for the quarter and year-to-date ended 30 September 2022

	(Rs. in Lakhs except as stated						
		Quarter ended Year-to-date ended					Year ended
Sl. No.	Particulars	30 September 2022	30 June 2022	30 September 2021	30 September 2022	30 September 2021	31 March 2022
110.		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	11,826.47	10,200.77	10,949.82	22,027.24	22,882.92	45,087.93
	(b) Other income	339.42	292.83	315.68	632.25	640.95	1,291.71
	Total income	12,165.89	10,493.60	11,265.50	22,659.49	23,523.87	46,379.64
2	Expenses						
2	(a) Cost of materials consumed	1,625.93	1.268.76	1,523.72	2,894.69	3,575.69	6,895.21
	(b) Employee benefits expense	1,924.50	1,896.78	1,659.28	3,821.28	3,224.84	6,867.66
	(c) Finance costs	485.39	473.63	389.85	959.02	781.34	1,625.56
	(d) Depreciation and amortisation expense	485.39 1,580.20	1,406.88	1,233.89	2.987.08	781.34 2,412.42	1,625.56 5,213.65
	(e) Other expenses	· · · · · · · · · · · · · · · · · · ·			,		,
	117	3,479.46	3,113.12	2,741.38	6,592.58	5,522.23	11,339.48
3	Total expenses Profit before tax [1-2]	9,095.48 3,070.41	8,159.17 2,334.43	7,548.12 3,717.38	17,254.65 5,404.84	15,516.52 8,007.35	31,941.56 14,438.08
	<u> </u>	3,070.41	2,334.43	3,/1/.38	5,404.84	8,007.35	14,438.08
4	Tax expense						
	(a) Current tax	675.00	712.00	1,054.00	1,387.00	2,194.00	3,902.00
	(b) Deferred tax	101.47	(98.28)	(69.16)	3.19	(146.88)	(253.00)
	(c) Tax pertaining to earlier years	-	-	-	-	-	(21.39)
	Total tax expense	776.47	613.72	984.84	1,390.19	2,047.12	3,627.61
5	Profit for the period/year [3 - 4]	2,293.94	1,720.71	2,732.54	4,014.65	5,960.23	10,810.47
6	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of defined benefit obligations	6.38	6.38	(2.55)	12.76	(5.10)	25.53
	(b) Income-tax relating to above item	(1.60)	(1.61)	0.64	(3.21)	1.28	(6.43)
	Other comprehensive income (loss) for the period/year (net of tax)	4.78	4.77	(1.91)	9.55	(3.82)	19.10
7	Total comprehensive income for the period/year [5 + 6]	2,298.72	1,725.48	2,730.63	4,024.20	5,956.41	10,829.57
8	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note						
0	5)	1,020.64	1,020.31	1,019.66	1,020.64	1,019.66	1,019.66
9	Other equity						45,978.38
10	Formings now equity shows (fees young of Do 1 cosh feels = -24)						
10	Earnings per equity share (face value of Re. 1 each fully paid up) (Refer Note 5)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	2.25	1.69	2.68	3.94	5.85	10.60
	- Basic (in Rs.) - Diluted (in Rs.)	2.23	1.69	2.66	3.94	5.83	10.54
	- Diluteu (iii Ks.)	2.24	1.68	2.66	3.92	5.81	10.54

#### Notes:

- 1. The above standalone financial results of Vijaya Diagnostic Centre Limited (Formerly known as "Vijaya Diagnostic Centre Private Limited") ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

  2. The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 10 November 2022. The statutory auditors have
- 2. The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 10 November 2022. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 30 September 2022. An unmodified report has been issued by them thereon.
- 3. The Board of Directors of the Company had proposed Final Dividend of Rs. 1 per equity share (Face value of Rs.1 each) for the year ended 31 March 2022. The same was approved by the shareholders in the Annual General Meeting of the Company held on 28 September 2022 and was paid on 12 October 2022.
- 4. The Company has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- 5. During the quarter ended 30 September 2022, the Company has issued 33,038 equity shares of face value of Rs. 1 each on exercise of employee stock options.
- 6. The Indian Parliament has approved the code on social security, 2020 ("Code") which, interalia, deals with employee benefits during employment and post employment. The code has been published in the Gazette of India. The effective date of the code is yet to be notified. The Company is in the process of evaluating the impact of the relevant provisions.

7. The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of

Vijaya Diagnostic Centre Limited

(Formerly known as 'Vijaya Diagnostic Centre Private Limited')

SURA SURENDRANATH REDDY

Digitally opiniol by SERR SUBBRINGARIEN MICHOET

[Thi child, childrenia, 1886—1819;
production—MODRIGHEST, NAVI THE DONNAMES TEST HEADING ZURING
MESTIPMEN THE RESOURCE HEADING THE DONNAMES TO MICHOE HEADING
MESTIPMENT THE RESOURCE HEADING THE DONNAMES THE MICHOE
MESTIPMENT THE RESOURCE HEADING THE LOSS OF THE MICHOET HEADING
MESTIPMENT THE RESOURCE HEADING THE MICHOET HEADING THE MIC

Dr. S. Surendranath Reddy Executive Chairman DIN Number: 00108599

Place: Hyderabad Date: 10 November 2022

		As at	A
No.	Particulars	30 September 2022 Unaudited	31 March 2
	ASSETS	Unaudited	Auditeu
I	Non-current assets		
-	(a) Property, plant and equipment	25,668.52	18,410.
	(b) Capital work-in-progress	855.28	3,410.
	(c) Right of use assets	20,979.84	16,715
	(d) Investment properties	1,104.72	1,110
	(e) Other intangible assets	187.49	135
	(f) Intangible assets under development	60.24	6
	(g) Financial assets		
	(i) Investments	487.35	487
	(ii) Loans	575.00	575
		1	740
	(iii) Other financial assets	789.86	
	(h) Deferred tax assets (net)	820.58	826
	(i) Non-current tax assets (net)	3.73	
	(j) Other non-current assets	1,484.44	2,227
	Total non-current assets	53,017.05	44,650
I	Current assets		
	(a) Inventories	434.51	409
	(b) Financial assets		
	(i) Investments	8,441.94	5,423
	(ii) Trade receivables	828.12	948
	(iii) Cash and cash equivalents	1,815.93	1,039
	(iv) Bank balances other than (iii) above	14,036.92	17,560
	(v) Loans	96.00	104
	(vi) Other financial assets	413.01	535
	(c) Other current assets	579.86	40:
	Total current assets	26,646.29	26,432
	TOTAL ASSETS (I + II)	79,663.34	71,083
I	EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Total equity	1,020.64 49,126.35 50,146.99	1,019 45,978 <b>46,998</b>
	Liabilities		
I	Non-current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	21,623.85	17,02:
	(b) Provisions	727.67	712
	(c) Other non-current liabilities	45.82	1
	Total non-current liabilities	22,397.34	17,749
П	Current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	1,334.69	1,250
	(ii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	10.06	1:
	Total outstanding dues of creditors other than micro enterprises and small enterprises	2,754.25	2,023
	(iii) Other financial liabilities	2,026.57	2,45
	(b) Provisions	258.55	154
	(c) Current tax liabilities (net)	359.58	89
	(d) Other current liabilities	375.31	343
	Total current liabilities	7,119.01	6,335
	Total liabilities ( II + III )	29,516.35	24,085
	TOTAL EQUITY AND LIABILITIES (I + II + III)	79,663.34	71,083
	Vijaya Diagnostic Co	ne Board of Directors of entre Limited Vijaya Diagnostic Centre Pri	vate Limited')

Dr. S. Surendranath Reddy

Executive Chairman

DIN Number: 00108599

Place: Hyderabad

Date: 10 November 2022

tandalo	ne Statement of Cashflows		(Rs. in L	akhs except as state
l. No.	Particulars		For the period ended 30 September 2022	For the period end 30 September 202
			(Unaudited)	(Unaudited)
A	Cash flow from operating activities			
	Profit before tax		5,404.84	8,007
	Adjustments for:			
	Depreciation and amortisation expense		2,987.08	2,412.
	Net (gain)/loss on sale/ retirement of property, plant and equipment		0.36	(24.2
	Interest income		(477.99)	(537.
	Profit on sale of mutual fund investments		(44.44)	-
	Provision for doubtful advances		20.00	-
	Provision for impairment of loans		8.97	-
	Employee stock option expense		36.63	66
	Fair value movement on financial instruments		(86.60)	(67.
	Finance costs		882.87	698
	Liability no longer required written back		002.07	0.
	Operating profit before changes in assets and liabilities		8,731.72	10,556.
	Working capital adjustments:		0,731.72	10,550.
	Decrease in trade receivables		120.55	12.
	Increase in inventories			l
	Decrease/ (increase) in other financial assets		(24.52)	(252.
	,		298.03	(1,265.
	Increase in other assets and deposits		(203.70)	(375.
	Decrease in trade payables		725.05	378
	Decrease in provisions and other liabilities		118.37	127
	(Increase) / decrease in other financial liabilities		(125.46)	508
	Cash generated from operations		9,640.04	9,690
	Income tax paid, net		(1,117.08)	(1,552.
	Net cash inflow from operating activities		8,522.96	8,137
В	Cash flows from investing activities			
ь	Acquisition of property, plant and equipment, capital work-in-progres (CWIP), other intangible assets and intangible assets under developmer (including capital advances and capital creditors)		(7,286.46)	(7,238.
	Proceeds from sale of property, plant and equipment		20.66	44
	Investment in debt oriented liquid mutual funds, net		(2,887.35)	
	Fixed deposits placed having original maturity of more than 3 months, net		3,527.56	2,230
	Loans given to subsidiaries		3,327.30	(425
	Interest received		271.15	,
		-	271.15	615
	Net cash outflow from investing activities		(6,354.44)	(4,773
C	Cash flows from financing activities			
	Proceeds from the exercise of employee stock option		108.76	
	Repayment of lease liabilities		(1,500.37)	(1,176.
	Net cash outflow from financing activities		(1,391.61)	(1,176.
	Not in succession and analysis of the control of th		77( 01	2 195
	Net increase in cash and cash equivalents (A + B + C)		776.91	2,187
	Cash and cash equivalents at the beginning of the financial period		1,039.02	631
	Cash and cash equivalents at end of the period		1,815.93	2,819
	Cash and cash equivalents as per above comprise of the following:			<u> </u>
			30 September 2022	30 September 2
	Cash on hand	}	•	•
	Balances with banks		56.43	64.
			1 750 50	2.754
	- in current accounts  Total cash and cash equivalents	-	1,759.50 <b>1,815.93</b>	2,754 2,819
		for and on behalf of the Vijaya Diagnostic Cent (Formerly known as 'Vij SURA SURENDRANATH	re Limited	
		DEDDY STUDENCH CONTROL	пульты под	
	Place: Hyderabad	Executive Chairman	-	
	Date: 10 November 2022	DIN Number: 00108599		

DIN Number: 00108599

Date: 10 November 2022

# B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City, Orwell, B Wing, 6<sup>th</sup> Floor, Unit-3, Sy No. 83/1, Plot No. 02, Raidurg, Hyderabad – 500 081 - India Telephone: +91 40 7182 2000 Fax: +91 40 7182 2399

Limited Review Report on unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') for the quarter ended 30 September 2022 and year-to-date results for the period from 01 April 2022 to 30 September 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

# To the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2022 and year-to-date results for the period from 01 April 2022 to 30 September 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
  - We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
- 4. The Statement includes the results of the following entities:

## **Parent**

a. Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

### **Subsidiaries**

- b. Medinova Diagnostic Services Limited
- c. VDC Diagnostics (Karnataka) LLP
- d. Doctorslab Medical Services Private Limited
- e. Medinova Millenium MRI Services LLP
- f. Namrata Diagnostic Centre Private Limited

## BSR & Associates LLP

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the interim financial results of 2 subsidiaries included in the Statement, whose interim financial results reflect total assets of Rs. 745.66 lakhs as at 30 September 2022 and total revenues of Rs. 261.69 lakhs and Rs. 511.63 lakhs, total net profit after tax of Rs. 35.99 lakhs and Rs. 65.79 lakhs and total comprehensive income of Rs. 35.99 lakhs and Rs. 65.79 lakhs, for the quarter ended 30 September 2022 and for the period from 01 April 2022 to 30 September 2022 respectively, and cash flows (net) of Rs. 22.96 lakhs for the period from 01 April 2022 to 30 September 2022, as considered in the unaudited consolidated financial results. These interim financial results have been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

### For B S R & Associates LLP

Chartered Accountants

Firm's Registration No.:116231W/W-100024

AMIT KUMAR AMIT KUMAR BAJAJ

BAJAJ

Date: 2022.11.10

12:58:01 +05'20'

12:58:01 +05'30'

**Amit Kumar Bajaj** 

Partner

Membership No.: 218685 UDIN:22218685BCRYRF9687

Hyderabad 10 November 2022



# Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') CIN: L85195TG2002PLC039075

Regd. Office: 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad-500029, Telangana, India
Corporate Office: No.6-3-883/F, FPA Building, Near Rajiv Gandhi Statute Lane Adjacent to Topaz Building, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Consolidated Financials Results for the quarter and year-to-date ended 30 September 2022

Quarter ended					(Rs. in Lakhs except Year-to-date ended Year e			
SI.	Particulars	30 September 2022	30 June 2022	30 September 2021	30 September 2022	30 September 2021	31 March 2022	
No.		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income							
	(a) Revenue from operations	12,074.93	10,436.21	11,270.73	22,511.14	23,539.38	46,236.99	
	(b) Other income	330.43	276.93	315.45	607.36	643.82	1,283.06	
	Total income	12,405.36	10,713.14	11,586.18	23,118.50	24,183.20	47,520.05	
2	Expenses							
	(a) Cost of materials consumed	1,665.35	1,303.28	1,623.85	2,968.63	3,732.26	7,149.91	
	(b) Employee benefits expense	1,974.18	1,947.60	1,709.50	3,921.78	3,324.05	7,065.94	
	(c) Finance costs	487.39	476.51	393.68	963.90	793.94	1,645.03	
	(d) Depreciation and amortisation expense	1,590.31	1,417.59	1,247.74	3,007.90	2,439.83	5,268.61	
	(e) Other expenses	3,561.23	3,196.01	2,822.57	6,757.24	5,682.68	11,652.13	
	Total expenses	9,278.46	8,340.99	7,797.34	17,619.45	15,972.76	32,781.62	
3	Profit before tax [1 - 2]	3,126.90	2,372.15	3,788.84	5,499.05	8,210.44	14,738.43	
4	Tax expense							
	(a) Current tax	678.16	715.37	1,065.82	1,393.53	2,239.92	3,963.56	
	(b) Deferred tax, net	102.01	(98.92)	(76.67)	3.09	(161.78)	(283.06	
	(c) Tax pertaining to earlier years	0.01	` <u>-</u> ´	· - ′	0.01	` <u>-</u>	(8.83	
	Total tax expense	780.18	616.45	989.15	1,396.63	2,078.14	3,671.67	
5	Profit for the period/year [3-4]	2,346.72	1,755.70	2,799.69	4,102.42	6,132.30	11,066.76	
6	Other comprehensive income		, i	·				
	Items that will not be reclassified to profit or loss							
	(a) Remeasurement of the defined benefit obligations	6.38	6.38	(2.77)	12.76	(5.54)	27.62	
	(b) Income-tax relating to above item	(1.60)	(1.61)	0.64	(3.21)	1.28	(6.96	
	Other comprehensive income (loss) for the period/year (net	4.78	4.77	(2.13)	9.55	(4.26)	20.66	
	of tax)							
7	Total comprehensive income for the period/year [5+6]	2,351.50	1,760.47	2,797.56	4,111.97	6,128.04	11,087.42	
	Profit for the period attributable to:							
	Owners of the Company	2,332.52	1,745.00	2,771.19	4,077.52	6,068.16	10,968.06	
	Non controlling interests	14.20	10.70	28.50	24.90	64.14	98.70	
	Other comprehensive income attributable to:							
	Owners of the Company	4.78	4.77	(2.04)	9.55	(4.09)	20.07	
	Non controlling interests	-	-	(0.09)	-	(0.17)	0.59	
	Total comprehensive income attributable to:							
	Owners of the Company	2,337.30	1,749.77	2,769.15	4,087.07	6,064.07	10,988.13	
	Non controlling interests	14.20	10.70	28.41	24.90	63.97	99.29	
8	Paid-up equity share capital (Face value of Re. 1 each)							
ð	(Refer Note 5)	1,020.64	1,020.31	1,019.66	1,020.64	1,019.66	1,019.66	
	(Refer Note 5)	1,020.04	1,020.31	1,019.00	1,020.04	1,019.00	1,019.00	
9	Other equity						45,802.27	
10	Earnings per equity share (face value of Re. 1 each fully							
	paid up) (Refer Note 5)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)	
	- Basic (in Rs.)	2.29	1.71	2.72	4.00	5.95	10.76	
	- Diluted (in Rs.)	2.27	1.70	2.70	3.98	5.91	10.69	

#### Notes:

1. The above consolidated financial results of Vijaya Diagnostic Centre Limited (formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

- 2. The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 10 November 2022. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 30 September 2022. An unmodified report has been issued by them thereon.
- 3. The Board of Directors of the Company had proposed Final Dividend of Rs. 1 per equity share (Face value of Rs.1 each) for the year ended 31 March 2022. The same was approved by the shareholders in the Annual General Meeting of the Company held on 28 September 2022 and was paid on 12 October 2022.
- 4. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- 5. During the quarter ended 30 September 2022, the Company has issued 33,038 equity shares of face value of Rs. 1 each on exercise of employee stock options.
- 6. The Indian Parliament has approved the code on social security, 2020 ("Code") which, interalia, deals with employee benefits during employment and post employment. The code has been published in the Gazette of India. The effective date of the code is yet to be notified. The Group is in the process of evaluating the impact of the relevant provisions.
- 7. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of

Vijaya Diagnostic Centre Limited

(Formerly known as 'Vijaya Diagnostic Centre Private Limited')

SURA
SURENDRAN
SURENDRAN
SURENDRAN
ATH REDDY

 Place: Hyderabad
 Executive Chairman

 Date: 10 November 2022
 DIN Number: 00108599

Consolidated Balance sheet (Rs. in Lakhs except as stated)

Consolia	ated Balance sheet		khs except as stated)
		As at	As at
Sl. No.	Particulars	30 September 2022	31 March 2022
		Unaudited	Audited
_	ASSETS		
I	Non-current assets		40.554.00
	(a) Property, plant and equipment	26,928.98	19,661.08
	(b) Capital work-in-progress	855.28	3,409.88
	(c) Right of use assets	20,979.84	16,715.25
	(d) Other intangible assets	188.03	135.68
	(e) Intangible assets under development	60.24	6.84
	(f) Goodwill on consolidation	533.75	533.75
	(g) Financial assets		
	(i) Investments	4.00	4.00
	(ii) Other financial assets	806.38	754.71
	(h) Deferred tax assets, (net)	879.52	885.81
	(i) Non-current tax assets, (net)	28.99	22.57
	(j) Other non-current assets	1,484.44	2,227.81
	Total non-current assets	52,749.45	44,357.38
II	Current assets		
	(a) Inventories	451.82	427.67
	(b) Financial assets		
	(i) Investments	8,441.94	5,423.55
	(ii) Trade receivables	858.23	977.09
	(iii) Cash and cash equivalents	1,903.35	1,104.99
	(iv) Bank balances other than (iii) above	14,580.41	18,130.69
	(v) Other financial assets	373.63	514.53
	(c) Other current assets	590.38	410.18
	Total current assets	27,199.76	26,988.70
	TOTAL ASSETS (I + II)	79,949.21	71,346.08
	EQUITY AND LIABILITIES	,	•
I	EQUITY AND LIABILITIES Equity		
1	1 1	1,020.64	1,019.66
	(a) Equity share capital		· · · · · · · · · · · · · · · · · · ·
	(b) Other equity	49,013.11	45,802.27
	Equity attributable to owners of the Company	50,033.75	46,821.93
	Non-controlling interest	157.21	132.31
	Total equity	50,190.96	46,954.24
	Liabilities		
II	Non-current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	21,623.85	17,025.97
	(b) Provisions	759.14	741.84
	(c) Other non-current liabilities	45.82	11.65
	Total non-current liabilities	22,428.81	17,779.46
Ш	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	11.37	63.46
	(ii) Lease liabilities	1,334.69	1,256.83
	(iii) Trade payables	1,554.07	1,250.05
	Total outstanding dues of micro and small enterprises	12.00	16.76
	Total outstanding dues of infero and small enterprises  Total outstanding dues of creditors other than micro and small enterprises		
	(iv) Other financial liabilities	2,861.63	2,147.11 2,480.30
		2,054.84	,
	(b) Provisions	313.59	208.63
	(c) Current tax liabilities, net	359.85	90.30
	(d) Other current liabilities	381.47	348.99
	Total current liabilities	7,329.44	6,612.38
	Total liabilities (II + III)	29,758.25	24,391.84
	TOTAL EQUITY AND LIABILITIES (I + II + III)	79,949.21	71,346.08

for and on behalf of the Board of Directors of

Vijaya Diagnostic Centre Limited

(Formerly known as 'Vijaya Diagnostic Centre Private Limited')

SURA
SURENDRANATH
REDDY

Digitally signed by GIBB GERMAN HISEOUT MR. Co. Market St. GIBB GERMAN HISEOUT MR. Co. GIBB GERMAN HI

Dr. S. Surendranath Reddy

Place: Hyderabad Executive Chairman
Date: 10 November 2022 DIN Number: 00108599

No	Particulars	For the period ended 30 September 2022	For the period ende 30 September 202
		Unaudited	Unaudited
- 1	Cash flow from operating activities		
- 1	Profit before tax	5,499.05	8,210.4
-	Adjustments for:		
	Depreciation and amortisation expense	3,007.90	2,439.8
	Net gain on sale/ retirement of property, plant and equipment	0.36	(24.26
	Interest income	(462.55)	(536.40
	Profit on sale of mutual fund investments	(44.44)	-
	Provision for credit impaired receivables	3.84	(0.22
	Provision for doubtful advances	20.00	-
	Fair value movement on financial instruments	(86.60)	(67.04
	Liabilities no longer required, written back	-	0.1
	Employee stock option expense	36.63	66.2
	Finance costs	885.24	722.6
	Bad debts written-off	-	0.0
	Operating profit before working capital changes Working capital adjustments:	8,859.43	10,811.3
	(Increase) in inventories	(24.15)	(263.2
	Decrease / (increase) in trade receivables	115.02	(28.4:
	Decrease / (increase) in other financial assets	297.92	(1,265.4
	(Increase) in other assets and deposits	(210.02)	(381.9
	Increase in trade payables	709.76	364.4
	Increase in provisions and other liabilities	120.92	213.8
	(Decrease) / increae in other financial liabilities	(126.08)	496.6
	Cash generated from operations	9,742.80	9,947.1
	Income tax paid, net	(1,130.41)	(1,557.83
	Net cash inflow from operating activities	8,612.39	8,389.3
B.	Cash flows from investing activities		
	Acquisition of property, plant and equipment, capital work-in-progress (CWIP), other		
	Intangible assets and intangible assets under development (including capital advances and	(7,323.06)	(7,337.9
	capital creditors)		
	Proceeds from sale of property, plant and equipment	20.35	45.6
	Investment in debt oriented liquid mutual funds, (net)	(2,887.35)	-
	Fixed deposits placed having original maturity of more than 3 months, (net)	3,546.45	2,175.1
	Interest received	274.61	617.9
	Net cash outflow from investing activities	(6,369.00)	(4,499.2
	Cash flows from financing activities		(227.4
- 1	Repayment of long-term borrowings	(50.00)	(327.4
- 1	(Repayments) to short-term borrowings, net	(52.09)	(27.2
	Proceeds from the exercise of employee stock option	108.76	-
- 1	Repayment of lease liabilities (including interest)	(1,500.37)	(1,176.7)
- 1	Interest paid	(1.33)	(168.1
-	Net cash outflow from financing activities	(1,445.03)	(1,699.6
	Net increase in cash and cash equivalents (A + B + C)	798.36	2,190.
	Cash and cash equivalents at the beginning of the year	1,104.99	668.5
$\overline{}$	Cash and cash equivalents at end of the year	1,903.35	2,858.9

Cash and cash equivalents as per above comprise of the following:

	30 September 2022	30 September 2021
Cash on hand	57.26	65.94
Balances with banks		
- in current accounts	1,846.09	2,793.04
Total cash and cash equivalents	1,903.35	2,858.98

for and on behalf of the Board of Directors of

Vijaya Diagnostic Centre Limited

(Formerly known as 'Vijaya Diagnostic Centre Private Limited')

SURA
SURENDRAN
SURENDRAN
ATH REDDY

Dr. S. Surendranath Reddy

Executive Chairman DIN Number: 00108599

Place: Hyderabad Date: 10 November 2022